Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05094089 · ClinicalTrials.gov registry record
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
A clinical trial of Hernia, Ventral and Hernia Incisional Ventral, sponsored by W.L.Gore & Associates.
- Active
- Registry status
- 320
- Enrollment target
- 15
- Study locations
NCT05094089: Active study of Hernia, Ventral and Hernia Incisional Ventral, sponsored by W.L.Gore & Associates.
NCT05094089 is a study of Hernia, Ventral and Hernia Incisional Ventral that is active but no longer recruiting, run by W.L.Gore & Associates. The registered enrollment target is 320 participants, above the 138-participant average among 7 other Hernia, Ventral trials with a reported enrollment target (132% higher). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05094089, a study of Hernia, Ventral and Hernia Incisional Ventral, is active but no longer recruiting, sponsored by W.L.Gore & Associates.
- ACTIVE NOT RECRUITING
- Registry status
- 320 participants
- Enrollment target
- 15
- Study locations
Study Summary
The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amenable to hernia mesh repair will be enrolled into two cohorts (US and EU cohort) and followed-up over the period of 60 months.
Primary Outcome
Hernia Recurrence Treated Location
Conditions Studied
Interventions
- DEVICE Hernia repair with mesh
Study Locations (15)
Other
- Ospedale Civile di Baggiovara - Baggiovara
- Vincenzo Monaldi Hospital - Naples
- Sapienza Università di Roma - Roma
- University Hospital Virgen Macarena - Department of General And Digestive Surgery - Seville
- Hospital Quirón Salud-Sagrado Corazón - Seville
- University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham - Birmingham
- Walsall Manor Hospital - Walsall
Georgia
- Emory Saint Joseph's Hospital - Atlanta
Massachusetts
- Tufts Medical Center - Boston
Michigan
- Corewell Health - Grand Rapids
New Mexico
- Lovelace Women's Hospital - Albuquerque
New York
- Stony Brook University Hospital - Stony Brook
North Carolina
- Novant Health New Hanover Regional Medical Center - Wilmington
South Carolina
- Prisma Health Greenville Memorial Hospital - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-02-24 |
| Est. Completion | 2030-07-31 |
What the registry record for NCT05094089 still lists
NCT05094089 is an observational study that tracks outcomes without assigning an intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, above the 138-participant average among 7 other Hernia, Ventral trials with a reported enrollment target (132% higher).
The record links to 3 conditions, with Hernia, Ventral appearing as the primary indexed condition, and to 1 intervention - of which Hernia repair with mesh is the first listed.
NCT05094089 lists 15 locations in 9 states (Other, Georgia, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05094089 about?
NCT05094089 is a clinical study titled "Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application". The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amena...
What is the current status of trial NCT05094089?
This trial is currently active not recruiting. The enrollment target is 320 participants. The study started on 2023-02-24. Estimated completion is 2030-07-31.
What conditions does trial NCT05094089 study?
This clinical trial studies the following conditions: Hernia, Ventral, Hernia Incisional Ventral, Hernia Incisional.
What interventions are being tested in trial NCT05094089?
The interventions under investigation include: Hernia repair with mesh (DEVICE).
Who is sponsoring clinical trial NCT05094089?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05094089 being conducted?
This trial has 15 study locations across Georgia, Massachusetts, Michigan, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hernia, Ventral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GORE® ENFORM Biomaterial Product Study
RECRUITING · NA
-
Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh
RECRUITING · NA
-
A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot
RECRUITING
-
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
ACTIVE NOT RECRUITING · NA
-
Abdominal Wall Tension in Patients Undergoing Ventral Hernia Repair Without Component Separation
ACTIVE NOT RECRUITING
-
RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI